Rokit’s diabetic foot treatment, which leverages AI to personalize tissue regeneration, achieves an average regeneration success rate of 82% with a single procedure. Compared to traditional treatments such as amputation or chronic wound care, this approach reduces treatment costs to approximately one-quarter of conventional methods. With an estimated 1.6 million diabetic foot patients annually in the United States, this technology promises significant cost savings for the healthcare system.
The insurance approval is expected to accelerate Rokit’s market entry into regions with high insurance barriers, including the Middle East and Europe, following its success in South America. Health authorities in these regions are likely to evaluate the economic and clinical benefits of autologous tissue regeneration therapy based on the U.S. precedent.
“This is the first instance of AI-driven regenerative medicine being integrated into the U.S. public insurance system,” said Seok-Hwan You, CEO of Rokit Healthcare. “We anticipate this will accelerate global insurance approvals and usher in a new era of personalized treatment through our hyper-personalized regeneration platform.”
Kim Kuk Ju, HEALTH IN NEWS TEAM
press@hinews.co.kr
